AR051989A1 - Derivados de quinolina como agentes antibacterianos - Google Patents

Derivados de quinolina como agentes antibacterianos

Info

Publication number
AR051989A1
AR051989A1 ARP050105141A ARP050105141A AR051989A1 AR 051989 A1 AR051989 A1 AR 051989A1 AR P050105141 A ARP050105141 A AR P050105141A AR P050105141 A ARP050105141 A AR P050105141A AR 051989 A1 AR051989 A1 AR 051989A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkyloxy
compound
polyhaloalkyl
het
Prior art date
Application number
ARP050105141A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36649056&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR051989(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR051989A1 publication Critical patent/AR051989A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente se refiere al uso de un compuesto para la manufactura de un medicamento para el tratamiento de una infeccion bacteriana, siendo dicho compuesto un compuesto de formula (1) su sal de adicion o de base farmacéuticamente aceptable, su forma estereoquímicamente isomérica o su forma de N-oxido, donde R1 es H, halo, polihaloalquilo C1-6, alquilo C1-6, Ar o Het; p es un numero entero igual a 1 o 2; R2 es alquiloxi C1-6, alquiloxi C1-6-alquiloxi C1-6 o alquiltio C1-6; R3 es Ar, Het o Het1; R4 y R5 cada uno es independientemente h, alquilo C1-6 o bencilo; o R4 y R5 juntos e incluyendo el N al cual están unidos pueden formar un radical seleccionado del grupo de pirrolidinilo, 2-pirrolinilo, 3-pirrolinilo, pirrolilo, imidazolidinilo, pirazolidinilo, 2-imidazolinilo, 2-pirazolinilo, imidazolilo, pirazolilo, triazolilo, piperidinilo, piridinilo, piperazinilo, piridazinilo, pirimidinilo, pirazinilo, triazinilo, morfolinilo y tiomorfolinilo, cada uno de dichos anillos puede estar sustituido opcionalmente con alquilo C1-6, halo, polihaloalquilo C1-6, hidroxi, hidroxialquilo C1-6, alquiloxi C1-6, amino, mono- o di(alquil C1-6)amino, alquiltio C1-6, alquiloxi C1-6alquilo C1-6, alquiltio C1-6alquilo C1-6 o pirimidinilo; R6 es H, halo, polihaloalquilo C1-6, alquilo C1-6, alquiloxi C1-6, alquiltio C1-6; o dos radicales R6 proximos pueden tomarse en forma conjunta para formar un radical bivalente de formula -CH=CH-CH=CH-; r es un numero entero igual a 1 o 2; R7 es H, alquilo C1-6, Ar, Het o Het1; siempre que la infeccion bacteriana no sea una infeccion Micobacteriana. Composicion farmacéutica. Reivindicacion 29: Un compuesto de la formula (1) donde el compuesto se selecciona entre los siguientes compuestos (CUADRO 1), su sal de adicion de ácido o base farmacéuticamente aceptable o su forma de N-oxido.
ARP050105141A 2005-06-08 2005-12-09 Derivados de quinolina como agentes antibacterianos AR051989A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05105023 2005-06-08
US11/296,918 US7709498B2 (en) 2005-06-08 2005-12-08 Quinoline derivatives as antibacterial agents

Publications (1)

Publication Number Publication Date
AR051989A1 true AR051989A1 (es) 2007-02-21

Family

ID=36649056

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050105141A AR051989A1 (es) 2005-06-08 2005-12-09 Derivados de quinolina como agentes antibacterianos

Country Status (28)

Country Link
US (1) US7709498B2 (es)
EP (1) EP1901743B1 (es)
CN (1) CN101232884B (es)
AP (1) AP2383A (es)
AR (1) AR051989A1 (es)
AU (1) AU2005242142B8 (es)
BR (1) BRPI0506121A (es)
CA (1) CA2528849C (es)
CY (1) CY1114990T1 (es)
DK (1) DK1901743T3 (es)
EE (1) EE05697B1 (es)
ES (1) ES2452736T3 (es)
HK (1) HK1122210A1 (es)
HR (1) HRP20140206T1 (es)
IL (1) IL187904A (es)
JO (1) JO2977B1 (es)
LV (1) LV13534B (es)
ME (1) ME01783B (es)
NO (1) NO340352B1 (es)
NZ (1) NZ563824A (es)
PA (1) PA8678901A1 (es)
PL (1) PL1901743T3 (es)
PT (1) PT1901743E (es)
RS (1) RS53191B (es)
SG (1) SG165348A1 (es)
SI (1) SI1901743T1 (es)
TR (1) TR200504891A2 (es)
WO (1) WO2006131519A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2395237T3 (es) * 2002-07-25 2013-02-11 Janssen Pharmaceutica N.V. Derivados de quinolina como compuestos intermedios para inhibidores micobacterianos
KR20130024969A (ko) * 2004-05-28 2013-03-08 얀센 파마슈티카 엔.브이. 약물 내성 마이코박테리아 질환 치료를 위한 치환된 퀴놀린 유도체의 용도
ES2610472T3 (es) * 2005-06-28 2017-04-27 Janssen Pharmaceutica Nv Derivados de quinolina como agentes antibacterianos
JO2855B1 (en) * 2005-08-03 2015-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
CA2858520A1 (en) * 2006-05-18 2007-11-29 Pharmacyclics Inc. Intracellular kinase inhibitors
JO2684B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان في Quinoline antibacterial derivatives
JO3271B1 (ar) * 2006-12-06 2018-09-16 Janssen Pharmaceutica Nv مشتقات الكوينولين المضادة للجراثيم
JO2683B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2970B1 (en) 2006-12-06 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
RU2404971C2 (ru) * 2008-12-02 2010-11-27 ЗАО "Фарм-Синтез" Новые производные хинолина, способ их получения, их применение для лечения микобактериальных инфекций, фармацевтическая композиция на их основе
WO2011058113A1 (en) * 2009-11-12 2011-05-19 Ucb Pharma S.A. Fused bicyclic pyridine and pyrazine derivatives as kinase inhibitors
CA2869718C (en) 2012-04-27 2021-05-11 Janssen Pharmaceutica Nv Antibacterial quinoline derivatives
PL2841426T3 (pl) 2012-04-27 2017-03-31 Janssen Pharmaceutica N.V. Przeciwbakteryjne pochodne chinoliny
EP3170810B1 (en) 2014-07-14 2018-09-19 Cisen Pharmaceutical Co., Ltd. Pyridine derivatives and anti-mycobacterial use thereof
CN105330595B (zh) * 2014-07-14 2019-12-10 上海嘉坦医药科技有限公司 吡啶衍生物及其作为抗分支杆菌的应用
RS64308B1 (sr) * 2015-01-27 2023-07-31 Janssen Pharmaceutica Nv Disperzibilni sastavi
CN108473428B (zh) * 2016-01-13 2021-07-23 上海嘉坦医药科技有限公司 一种吡啶衍生物类化合物的制备方法及其中间体和晶型
CN112574175B (zh) * 2019-09-29 2023-11-14 南京长澳医药科技有限公司 喹啉类化合物、其制备方法和用途
CN110804016B (zh) * 2019-12-05 2022-11-04 福建省微生物研究所 抗结核分枝杆菌的二芳基喹啉衍生物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG20543A (en) 1992-10-30 1999-07-31 Procter & Gamble Process for preparing of novel antimicrobial -5- (n-heterosubstituted amino) quinolones
GB9317491D0 (en) 1993-08-23 1993-10-06 Fujisawa Pharmaceutical Co New compound and a process for preparation thereof
US5965572A (en) * 1996-10-28 1999-10-12 The United States Of America As Respresented By The Secretary Of The Army Methods for treating antibiotic-resistant infections
US6103905A (en) 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
AU2717899A (en) 1998-01-26 1999-08-09 Smithkline Beecham Plc Quinoline derivatives as antibacterials
ES2395237T3 (es) * 2002-07-25 2013-02-11 Janssen Pharmaceutica N.V. Derivados de quinolina como compuestos intermedios para inhibidores micobacterianos
CN1910177B (zh) 2004-01-23 2010-05-05 詹森药业有限公司 取代的喹啉及其作为分枝杆菌抑制剂的用途
KR20130024969A (ko) 2004-05-28 2013-03-08 얀센 파마슈티카 엔.브이. 약물 내성 마이코박테리아 질환 치료를 위한 치환된 퀴놀린 유도체의 용도

Also Published As

Publication number Publication date
BRPI0506121A (pt) 2007-02-13
DK1901743T3 (da) 2014-03-31
JO2977B1 (en) 2016-03-15
IL187904A0 (en) 2008-03-20
CN101232884B (zh) 2016-01-20
AU2005242142B2 (en) 2011-06-23
CN101232884A (zh) 2008-07-30
EP1901743A1 (en) 2008-03-26
AP2007004264A0 (en) 2007-12-31
ES2452736T3 (es) 2014-04-02
EP1901743B1 (en) 2013-12-25
TR200504891A2 (tr) 2007-01-22
ME01783B (me) 2014-09-20
HRP20140206T1 (hr) 2014-04-11
IL187904A (en) 2015-05-31
AP2383A (en) 2012-03-16
EE05697B1 (et) 2014-02-17
HK1122210A1 (zh) 2009-05-15
CA2528849C (en) 2014-01-14
PA8678901A1 (es) 2007-01-17
EE200500034A (et) 2007-02-15
PL1901743T3 (pl) 2014-05-30
CA2528849A1 (en) 2006-12-08
NZ563824A (en) 2010-11-26
LV13534B (en) 2007-06-20
SG165348A1 (en) 2010-10-28
US20060281741A1 (en) 2006-12-14
CY1114990T1 (el) 2016-12-14
WO2006131519A1 (en) 2006-12-14
SI1901743T1 (sl) 2014-04-30
AU2005242142B8 (en) 2011-11-10
NO340352B1 (no) 2017-04-10
PT1901743E (pt) 2014-03-25
AU2005242142A1 (en) 2007-01-04
NO20080064L (no) 2008-01-04
US7709498B2 (en) 2010-05-04
RS53191B (en) 2014-06-30

Similar Documents

Publication Publication Date Title
AR051989A1 (es) Derivados de quinolina como agentes antibacterianos
CY1124680T1 (el) Παραγωγα 8-[6-[3-(αμινο)προποξυ]-3-πυριδυλο]-1-ισοπροπυλο-ιμιδαζο[4,5-c]κινολιν-2-ονης ως εκλεκτiκοι ρυθμιστες κινασης μεταλλαγμενης αταξιας τελαγγειεκτασιας (atm) για τη θεραπευτικη αγωγη του καρκινου
MY189118A (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives
PH12018500958A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
CY1114908T1 (el) Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες
PH12016502168B1 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
CY1114318T1 (el) Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
BRPI0510560A (pt) pirido[2,3-d] pirimidin-7-onas pirrolil substituìdas e seus derivados como agentes terapêuticos
PH12018500957A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
EA201000615A1 (ru) Производные имидазо[1,2-а]пиридина, применимые в качестве ингибиторов апк (активиноподобной киназы)
MX2007003603A (es) Metodos para preparar compuestos de indazol.
PH12019502086A1 (en) Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
CY1113535T1 (el) Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες
SE0301320D0 (sv) Positive modulators of nicotinic acetylcholine receptors
CY1113579T1 (el) Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες
MX2018011283A (es) Compuestos de cinnolin-4-amina y su uso en el tratamiento del cancer.
MX2019004375A (es) Inhibidores de bromodominios.
AR057654A1 (es) Derivados de quinolina como agentes antibacterianos
MX2017011423A (es) Derivados de 7-(morfolin-4-il)pirazolo[1,5-a]pirimidina que son utiles para el tratamiento de enfermedades inmunes o inflamatorias o cancer.
EA200500800A1 (ru) Производные хинолина в качестве антибактериальных агентов
BRPI0414778A (pt) 6-aril-7-halo-imidazo[1,2-a]pirimidinas como agentes anticáncer
TW200716109A (en) Quinoline derivatives as antibacterial agents
MY163500A (en) Quinoline derivatives as antibacterial agents
MX2009009768A (es) Derivados de quinolina, composiciones farmaceuticas que los comprenden y su uso en eltratamiento de enfermedades del sistema nervisos central y periferico.

Legal Events

Date Code Title Description
FB Suspension of granting procedure